CA-LASERFICHE
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced that CRN®, a brand of The Channel Company, named three Laserfiche channel leaders to its 2024 Channel Chiefs list: Taylor Grosso, senior director of Global Channels and Alliances, Charles Suzara, associate director – west, and Vicki VanValin, vice president of sales. The prestigious CRN Channel Chiefs list, released annually, recognizes IT vendor and distribution executives who are driving strategy and setting the channel agenda for their companies.
“The IT channel has had to navigate incredible change in recent years — from economic uncertainty to the acceleration of digital transformation and rise of generative AI,” said Laserfiche CEO Karl Chan. “Laserfiche’s channel leadership has risen to the challenge of supporting our partners and empowering them to embrace these changes proactively. Taylor, Charles and Vicki are providing the channel with strategies, resources and programs that enable our partners to capture new business opportunities, solve customer problems and grow their revenue streams.”
Grosso manages Laserfiche’s global channel sales team, focusing on channel growth and providing solution providers with the necessary support to develop, manage and maximize sales opportunities. He has developed a sales model that emphasizes relevant and timely educational opportunities, training and support for channel partners.
Suzara is responsible for a team of channel managers covering 25 states, representing a diverse range of channel partners and industries served. As Laserfiche expands its footprint in the enterprise space, Suzara has been instrumental in working with channel partners to approach larger organizations with more complex needs, while still supporting some of the company’s newest partners in getting up and running quickly.
VanValin joined Laserfiche in 2023, bringing 25 years of experience in sales leadership and business development for global technology companies. During her time at Laserfiche, she has driven key changes to the company’s channel program in response to changing market needs, to set channel partners up for sustainable success. Under her leadership, Laserfiche is modernizing its channel partner program while building a thriving channel partner ecosystem that provides expanded resources and capabilities, enhances customer loyalty and encourages innovation.
“These channel evangelists are dedicated to supporting solution providers and achieving growth by implementing robust partner programs and unique business strategies,” said Jennifer Follett, VP, US Content, and executive editor, CRN, at The Channel Company. “Their efforts are instrumental in helping partners bring essential solutions to market. The Channel Company is pleased to acknowledge these prominent channel leaders and looks forward to chronicling their achievements throughout the year.”
The Channel Chiefs list showcases the top leaders throughout the IT channel ecosystem who work tirelessly to ensure mutual success with their partners and customers.
CRN’s 2024 Channel Chiefs list will be featured in the February 2024 issue of CRN® Magazine and online at www.CRN.com/ChannelChiefs.
To learn more about the Laserfiche Solution Provider Program, visit laserfiche.com/partners/solution-provider-program/.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter/X | LinkedIn | Facebook
About The Channel Company
The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers and end users. Backed by more than 40 years of unequalled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace. http://www.thechannelcompany.com/
Follow The Channel Company: Twitter, LinkedIn, and Facebook.
© 2024. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206729035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom